DOCSLIB.ORG

Leuprorelin (Prostap®) for the Treatment of Prostate Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Leuprorelin (Prostap®) for the Treatment of Prostate Cancer COMMISSIONING SUPPORT Leuprorelin (Prostap®) For the treatment of prostate cancer Key issue: Can leuprorelin be considered to be cost-effective on the basis of its effect on plasma testosterone and cost? Committee opinion: The Committee agreed that the reduction in plasma testosterone produced by leuprorelin was an acceptable surrogate marker of efficacy in prostate cancer, given the clinical experience of this and other luteinising hormone- releasing hormone (LHRH) analogues. Prescribing guidance: Category B (suitable for restricted prescribing under defined conditions) Leuprorelin for prostate cancer can be prescribed in primary care upon the advice of a specialist, using a shared care agreement. (A Q rating was not considered because of the use of a surrogate marker for the decision.) Commissioning guidance: • If the assumption is made that the LHRH analogues have equivalent efficacy and safety, and ignoring the differences in licensed indications, the main commissioning issue is cost, and the cheapest preparation should be used. • The comparative costs of the different LHRH analogues depend on whether the monthly or three-monthly preparation is used. • Commissioners should engage with providers to reach agreement on product use to achieve the most economic model for LHRH agonist use across the health economy. This should take into account product price, local discounts available from manufacturers, and fees paid for administration. • The LHRH agonists available are buserelin, goserelin, leuprorelin and triptorelin; their licensed indications for the treatment of prostate cancer differ. Objectives month, or 11.25 mg injected subcutaneously every three months. • To appraise the clinical evidence for the efficacy and safety of leuprorelin for the treatment of For metastatic prostate cancer, androgen deprivation (or prostate cancer withdrawal) therapy, either by orchidectomy or drug- • To consider the financial implications induced castration, has been considered to be an effective • To consider the commissioning issues treatment for over 60 years.2 Androgen deprivation therapy is also used as adjunct therapy for patients Background undergoing radiotherapy or prostatectomy for high-risk Leuprorelin is one of the LHRH agonists, which localised or locally advanced prostate cancer. cause suppression of the secretion of testosterone. Androgen deprivation is achieved using orchidectomy, They have been used since the mid-1980s as an LHRH agonists, the anti-androgens bicalutamide, alternative to orchidectomy in advanced metastatic cyproterone and flutamide, and degaralix, a prostate cancer. gonadotrophin-releasing hormone antagonist. The indications for leuprorelin for the treatment of National guidance prostate cancer are:1 • metastatic prostate cancer In April 2008, the National Institute for Clinical Excellence • locally advanced prostate cancer, as an alternative (NICE) published a Clinical Guideline on prostate cancer.2 to surgical castration NICE recommended that for metastatic prostate cancer, • as an adjuvant treatment to radiotherapy in patients bilateral orchidectomy should be offered as an alternative with high-risk localised or locally advanced prostate to continuous LHRH agonist therapy. For localised and cancer locally advanced prostate cancer, adjuvant “hormonal • as an adjuvant treatment to radical prostatectomy therapy” [type not specified] was recommended for a in patients with locally advanced prostate cancer at minimum of two years in men receiving radical high risk of disease progression radiotherapy for localised prostate cancer who have a (Leuprorelin is not licensed for neo-adjuvant Gleason score ≥ 8. Adjuvant “hormonal therapy” in treatment.) addition to radical prostatectomy was not recommended other than in a clinical trial. For locally advanced prostate The recommended dose of leuprorelin is 3.75 mg cancer, neoadjuvant and concurrent LHRH agonist therapy injected subcutaneously or intramuscularly every October 2010 Page 1 of 2 was recommended for three to six months in men Commissioning issues receiving radical radiotherapy. When considering cost effectiveness and which product to Appraisal of clinical evidence for efficacy and use, patient frequency of GP surgery attendance, the safety of leuprorelin frequency of drug administration and associated monitoring, and any GP practice fees for administration of Advanced metastatic prostate cancer the injections need to be taken into account. Fees for drug There is evidence that goserelin therapy produces a administration may vary since goserelin is an implant and reduction in serum testosterone equivalent to leuprorelin is a liquid injection. bilateral orchidectomy.3,4 Leuprorelin has not been compared with orchidectomy, but similar reductions References in testosterone (to near castration levels in over 90% 1. Leuprorelin acetate ( Prostap 3 Depot Injection 11.25mg and of patients) have been reported in uncontrolled Prostap SR). Takeda UK Ltd. 2010. trials5-7 and four trials comparing its effect with that of http://emc.medicines.org.uk/emc 8 9,10 11 2. National Institute for Health and Clinical Excellence. Clinical goserelin, triptorelin, diethylstilboestrol and Guideline 58. Prostate cancer. NICE. 2008. 12 degarelix. www.nice.org.uk/nicemedia/pdf/CG58EvidenceReview.pdf 3. Kaisary AV et al. Comparison of LHRH analogue (Zoladex) with Patient-oriented outcomes were used in the orchiectomy in patients with metastatic prostatic carcinoma. Br J comparison with diethylstilboestrol, an open-label Urol 1991;67:502-508 randomised trial that involved 186 patients with 4. Soloway MS et al. Zoladex versus orchiectomy in treatment of 11 advanced prostate cancer: a randomized trial. Urology metastatic prostate cancer. Serum testosterone 1991;37:46-51. concentrations (the main outcome measure) were 5. Perez-Marreno R et al. A six-month, open-label study assessing similarly suppressed in both groups, measured for a new formulation of leuprolide 7.5 mg for suppression of up to 48 weeks. Clinical response to treatment testosterone in patients with prostate cancer. Clin Ther 2002;24:1902-1914. (based on a set of criteria) were also similar 6. Sharifi R, Browneller R. Serum testosterone suppression and between the groups. Survival rates were not potential for agonistic stimulation during chronic treatment with different between the groups at one year (87% for monthly and 3-month depot formulations of leuprolide acetate for leuprorelin and 78% for diethylstilboestrol). advanced prostate cancer. J Urol 2002;168:1001-1004. 7. Jocham D. Leuprorelin three-month depot in the treatment of Localised and locally advanced prostate cancer advanced and metastatic prostate cancer: long-term follow-up No relevant studies were identified using leuprorelin results. Urol Int 1998;60 Suppl 2:18-24. 8. Fujii Y et al. Equivalent and sufficient effects of leuprolide acetate as an alternative to surgical castration in locally and goserelin acetate to suppress serum testosterone levels in advanced prostate cancer, or as adjuvant therapy patients with prostate cancer. BJU Int 2008;101:1096-1100. with either radiotherapy or prostatectomy. 9. Heyns CF et al. Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer. BJU Int Adverse effects 2003;92:226-231. 10. Kuhn JM et al. A randomised comparison of the clinical and In clinical trials, reported adverse events with hormonal effects of two GnRH agonists in patients with prostate hormone therapy included hot flushes, breast cancer. Eur Urol 1997;32:397-403. tenderness, decreased libido, asthenia, dyspnoea 11. The Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med 1984;311:1281- on exertion, depression and diarrhoea. Several 1286. retrospective studies of androgen deprivation 12. Klotz L et al. The efficacy and safety of degarelix: a 12-month, therapy (including LHRH agonists, anti-androgens comparative, randomized, open-label, parallel-group phase III and orchidectomy, or not specified) have reported a study in patients with prostate cancer. BJU Int 2008;102:1531- 1538. higher risk of cardiovascular disease or myocardial 13,14 15,16 17 13. D'Amico AV et al. Influence of androgen suppression therapy for infarction, fractures and diabetes. prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007;25:2420-2425. Financial issues 14. Tsai HK et al. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst Costs at current prices from MIMS and the Drug 2007;99:1516-1524. Tariff for a year’s treatment: 15. Smith MR et al. Risk of clinical fractures after gonadotropin- leuprorelin (Prostap) 3.75 mg monthly £903 releasing hormone agonist therapy for prostate cancer. J Urol leuprorelin (Prostap) 11.25 mg three-monthly £903 2006;175:136-139. goserelin (generic Novgos) 3.6 mg monthly £808 16. Abrahamsen B et al. Fracture risk in Danish men with prostate goserelin (Zoladex) 3.6 mg every 28 days £847 cancer: a nationwide register study. BJU Int 2007;100:749-754. 17. Derweesh IH et al. Risk of new-onset diabetes mellitus and goserelin (Zoladex) 10.8 mg every 12 weeks £1,021 worsening glycaemic variables for established diabetes in men triptorelin 11.25 mg three-monthly £828 undergoing androgen-deprivation therapy for prostate cancer. triptorelin 3 mg every 28 days £899 BJU Int 2007;100:1060-1065. Launch date: 1990 Manufacturer: Takeda PL 16189/0008, 0009 WARNING: This sheet should be read in conjunction with the Summary of Product Characteristics This guidance is based upon the published information available in English at the time the drug was considered. It remains open to review in the event of significant new evidence emerging. MTRAC can be contacted at the Dept. of Medicines Management, School of Pharmacy, Keele University, Keele, Staffs ST5 5BG Tel: 01782 584131 Fax: 01782 713586 Email: [email protected] Web: www.mtrac.co.uk Date: October 2010 ©Midlands Therapeutics Review & Advisory Committee SS02/10 .
Load more

Recommended publications
  • Hormones and Breeding
    IN-DEPTH: REPRODUCTIVE ENDOCRINOLOGY Hormones and Breeding Carlos R.F. Pinto, MedVet, PhD, Diplomate ACT Author’s address: Theriogenology and Reproductive Medicine, Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH 43210; e-mail: [email protected]. © 2013 AAEP. 1. Introduction affected by PGF treatment to induce estrus. In The administration of hormones to mares during other words, once luteolysis takes place, whether breeding management is an essential tool for equine induced by PGF treatment or occurring naturally, practitioners. Proper and timely administration of the events that follow (estrus behavior, ovulation specific hormones to broodmares may be targeted to and fertility) are essentially similar or minimally prevent reproductive disorders, to serve as an aid to affected (eg, decreased signs of behavioral estrus). treating reproductive disorders or hormonal imbal- Duration of diestrus and interovulatory intervals ances, and to optimize reproductive efficiency, for are shortened after PGF administration.1 The example, through induction of estrus or ovulation. equine corpus luteum (CL) is responsive to PGF These hormones, when administered exogenously, luteolytic effects any day after ovulation; however, act to control the duration and onset of the different only CL Ͼ5 days are responsive to one bolus injec- stages of the estrous cycle, specifically by affecting tion of PGF.2,3 Luteolysis or antiluteogenesis can duration of luteal function, hastening ovulation es- be reliably achieved in CL Ͻ5 days only if multiple pecially for timed artificial insemination and stimu- PGF treatments are administered. For that rea- lating myometrial activity in mares susceptible to or son, it became a widespread practice to administer showing delayed uterine clearance.
    [Show full text]
  • Leuprolide Acetate)
    For Pediatric Use LUPRON® INJECTION (leuprolide acetate) Rx only DESCRIPTION Leuprolide acetate is a synthetic nonapeptide analog of naturally occurring gonadotropin releasing hormone (GnRH or LH-RH). The analog possesses greater potency than the natural hormone. The chemical name is 5- oxo -L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl- N-ethyl-L-prolinamide acetate (salt) with the following structural formula: LUPRON INJECTION is a sterile, aqueous solution intended for daily subcutaneous injection. It is available in a 2.8 mL multiple dose vial containing leuprolide acetate (5 mg/mL), sodium chloride, USP (6.3 mg/mL) for tonicity adjustment, benzyl alcohol, NF as a preservative (9 mg/mL), and water for injection, USP. The pH may have been adjusted with sodium hydroxide, NF and/or acetic acid, NF. CLINICAL PHARMACOLOGY Leuprolide acetate, a GnRH agonist, acts as a potent inhibitor of gonadotropin secretion when given continuously and in therapeutic doses. Animal and human studies indicate that following an initial stimulation of gonadotropins, chronic administration of leuprolide acetate results in suppression of ovarian and testicular steroidogenesis. This effect is reversible upon discontinuation of drug therapy. Leuprolide acetate is not active when given orally. Pharmacokinetics A pharmacokinetic study of leuprolide acetate in children has not been performed. Absorption Page 1 In adults, bioavailability by subcutaneous administration is comparable to that by intravenous administration. Distribution The mean steady-state volume of distribution of leuprolide following intravenous bolus administration to healthy adult male volunteers was 27 L. In vitro binding to human plasma proteins ranged from 43% to 49%.
    [Show full text]
  • CASODEX (Bicalutamide)
    HIGHLIGHTS OF PRESCRIBING INFORMATION • Gynecomastia and breast pain have been reported during treatment with These highlights do not include all the information needed to use CASODEX 150 mg when used as a single agent. (5.3) CASODEX® safely and effectively. See full prescribing information for • CASODEX is used in combination with an LHRH agonist. LHRH CASODEX. agonists have been shown to cause a reduction in glucose tolerance in CASODEX® (bicalutamide) tablet, for oral use males. Consideration should be given to monitoring blood glucose in Initial U.S. Approval: 1995 patients receiving CASODEX in combination with LHRH agonists. (5.4) -------------------------- RECENT MAJOR CHANGES -------------------------- • Monitoring Prostate Specific Antigen (PSA) is recommended. Evaluate Warnings and Precautions (5.2) 10/2017 for clinical progression if PSA increases. (5.5) --------------------------- INDICATIONS AND USAGE -------------------------- ------------------------------ ADVERSE REACTIONS ----------------------------- • CASODEX 50 mg is an androgen receptor inhibitor indicated for use in Adverse reactions that occurred in more than 10% of patients receiving combination therapy with a luteinizing hormone-releasing hormone CASODEX plus an LHRH-A were: hot flashes, pain (including general, back, (LHRH) analog for the treatment of Stage D2 metastatic carcinoma of pelvic and abdominal), asthenia, constipation, infection, nausea, peripheral the prostate. (1) edema, dyspnea, diarrhea, hematuria, nocturia, and anemia. (6.1) • CASODEX 150 mg daily is not approved for use alone or with other treatments. (1) To report SUSPECTED ADVERSE REACTIONS, contact AstraZeneca Pharmaceuticals LP at 1-800-236-9933 or FDA at 1-800-FDA-1088 or ---------------------- DOSAGE AND ADMINISTRATION ---------------------- www.fda.gov/medwatch The recommended dose for CASODEX therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening).
    [Show full text]
  • Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals
    Journal of Clinical Medicine Review Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals Carlotta Cocchetti 1, Jiska Ristori 1, Alessia Romani 1, Mario Maggi 2 and Alessandra Daphne Fisher 1,* 1 Andrology, Women’s Endocrinology and Gender Incongruence Unit, Florence University Hospital, 50139 Florence, Italy; [email protected] (C.C); jiska.ristori@unifi.it (J.R.); [email protected] (A.R.) 2 Department of Experimental, Clinical and Biomedical Sciences, Careggi University Hospital, 50139 Florence, Italy; [email protected]fi.it * Correspondence: fi[email protected] Received: 16 April 2020; Accepted: 18 May 2020; Published: 26 May 2020 Abstract: Introduction: To date no standardized hormonal treatment protocols for non-binary transgender individuals have been described in the literature and there is a lack of data regarding their efficacy and safety. Objectives: To suggest possible treatment strategies for non-binary transgender individuals with non-standardized requests and to emphasize the importance of a personalized clinical approach. Methods: A narrative review of pertinent literature on gender-affirming hormonal treatment in transgender persons was performed using PubMed. Results: New hormonal treatment regimens outside those reported in current guidelines should be considered for non-binary transgender individuals, in order to improve psychological well-being and quality of life. In the present review we suggested the use of hormonal and non-hormonal compounds, which—based on their mechanism of action—could be used in these cases depending on clients’ requests. Conclusion: Requests for an individualized hormonal treatment in non-binary transgender individuals represent a future challenge for professionals managing transgender health care. For each case, clinicians should balance the benefits and risks of a personalized non-standardized treatment, actively involving the person in decisions regarding hormonal treatment.
    [Show full text]
  • Hertfordshire Medicines Management Committee (Hmmc) Nafarelin for Endometriosis Amber Initiation – Recommended for Restricted Use
    HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) NAFARELIN FOR ENDOMETRIOSIS AMBER INITIATION – RECOMMENDED FOR RESTRICTED USE Name: What it is Indication Date Decision NICE / SMC generic decision status Guidance (trade) last revised Nafarelin A potent agonistic The hormonal December Final NICE NG73 2mg/ml analogue of management of 2020 Nasal Spray gonadotrophin endometriosis, (Synarel®) releasing hormone including pain relief and (GnRH) reduction of endometriotic lesions HMMC recommendation: Amber initiation across Hertfordshire (i.e. suitable for primary care prescribing after specialist initiation) as an option in endometriosis Background Information: Gonadorelin analogues (or gonadotrophin-releasing hormone agonists [GnRHas]) include buserelin, goserelin, leuprorelin, nafarelin and triptorelin. The current HMMC decision recommends triptorelin as Decapeptyl SR® injection as the gonadorelin analogue of choice within licensed indications (which include endometriosis) link to decision. A request was made by ENHT to use nafarelin nasal spray as an alternative to triptorelin intramuscular injection during the COVID-19 pandemic. The hospital would provide initial 1 month supply, then GPs would continue for further 5 months as an alternative to the patient attending for further clinic appointments for administration of triptorelin. Previously at ENHT, triptorelin was the only gonadorelin analogue on formulary for gynaecological indications. At WHHT buserelin nasal spray 150mcg/dose is RED (hospital only) for infertility & endometriosis indications. Nafarelin nasal spray 2mg/ml is licensed for: . The hormonal management of endometriosis, including pain relief and reduction of endometriotic lesions. Use in controlled ovarian stimulation programmes prior to in-vitro fertilisation, under the supervision of an infertility specialist. Use of nafarelin in endometriosis aims to induce chronic pituitary desensitisation, which gives a menopause-like state maintained over many months.
    [Show full text]
  • Statistical Analysis Plan
    Title: An Open label, Multicenter Study to Assess the Safety and Efficacy of Leuprorelin in the Treatment of Central Precocious Puberty NCT Number: NCT02427958 SAP Approve Date: 01 June 2017 Certain information within this Statistical Analysis Plan has been redacted (ie, specific content is masked irreversibly from view with a black/blue bar) to protect either personally identifiable (PPD) information or company confidential information (CCI). This may include, but is not limited to, redaction of the following: Named persons or organizations associated with the study. Proprietary information, such as scales or coding systems, which are considered confidential information under prior agreements with license holder. • Other information as needed to protect confidentiality of Takeda or partners, personal information, or to otherwise protect the integrity of the clinical study. Takeda Statistical Analysis Plan Leuprorelin-4001 Version: 1.0 An Open label, Multicenter Study to Assess the Safety and Efficacy of Leuprorelin in the Treatment of Central Precocious Puberty Leuprorelin-4001, Leuprorelin in the Treatment of Central Precocious Puberty Statistical Analysis Plan Version: 1.0 Date: 01 June 2017 1 PPD PPD Takeda Statistical Analysis Plan Leuprorelin-4001 Version: 1.0 TABLE OF CONTENTS ABBREVIATIONS ........................................................................................................................ 6 1. INTRODUCTION ...............................................................................................................
    [Show full text]
  • Degarelix for Treating Advanced Hormone- Dependent Prostate Cancer
    CONFIDENTIAL UNTIL PUBLISHED NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Final appraisal determination Degarelix for treating advanced hormone- dependent prostate cancer This guidance was developed using the single technology appraisal (STA) process 1 Guidance 1.1 Degarelix is recommended as an option for treating advanced hormone-dependent prostate cancer, only in adults with spinal metastases who present with signs or symptoms of spinal cord compression. 1.2 People currently receiving treatment initiated within the NHS with degarelix that is not recommended for them by NICE in this guidance should be able to continue treatment until they and their NHS clinician consider it appropriate to stop. 2 The technology 2.1 Degarelix (Firmagon, Ferring Pharmaceuticals) is a selective gonadotrophin-releasing hormone antagonist that reduces the release of gonadotrophins by the pituitary, which in turn reduces the secretion of testosterone by the testes. Gonadotrophin- releasing hormone is also known as luteinising hormone-releasing hormone (LHRH). Because gonadotrophin-releasing hormone antagonists do not produce a rise in hormone levels at the start of treatment, there is no initial testosterone surge or tumour stimulation, and therefore no potential for symptomatic flares. National Institute for Health and Care Excellence Page 1 of 71 Final appraisal determination – Degarelix for treating advanced hormone-dependent prostate cancer Issue date: April 2014 CONFIDENTIAL UNTIL PUBLISHED Degarelix has a UK marketing authorisation for the ‘treatment of adult male patients with advanced hormone-dependent prostate cancer’. It is administered as a subcutaneous injection. 2.2 The most common adverse reactions with degarelix are related to the effects of testosterone suppression, including hot flushes and weight increase, or injection site reactions (such as pain and erythema).
    [Show full text]
  • Altered Cognitive Function in Men Treated for Prostate
    Altered Cognitive Function in Men Treated for Prostate Cancer with LHRH Analogues and Cyproterone Acetate: A Randomised Controlled Trial H. J. Green PhD1,2, K. I. Pakenham PhD1, B. C. Headley PhD3, J. Yaxley FRACS3, D. L. Nicol FRACS2,4, P. N. Mactaggart FRACS2,5, C. Swanson PhD2, R. B. W atson FRACS6, & R. A. Gardiner MD2,3 1School of Psychology and 2Department of Surgery, The University of Queensland, 3Royal Brisbane, 4Princess Alexandra, 5Queen Elizabeth II & 6Mater Hospitals, Brisbane, Queensland, Australia In conjunction with the Northern Section of the Urological Society of Australasia Correspondence should be addressed to: Dr R. A. Gardiner, Department of Surgery, The University of Queensland, Brisbane, Qld 4072, Australia Fax: +61 7 3365 5559; Phone: +61 7 3365 5233; Email: f.gardiner@ mailbox.uq.edu.au This work was wholly funded by Queensland Cancer Fund. **PREPRINT. Final version published in British Journal of Urology (BJU: International) (2002), 90, 427-432 ** Short Title: COGNITIVE CHANGES W ITH HORMONAL MEDICATION 2 Objective. Luteinising hormone releasing hormone (LHRH) analogues have been associated with memory impairments in women using these drugs for gynaecological conditions. This is the first systematic investigation of the cognitive effects of LHRH analogues in male patients. Methods. 82 men with non-localised prostate cancer were randomly assigned to receive continuous leuprorelin (LHRH analogue), goserelin (LHRH analogue), cyproterone acetate (steroidal antiandrogen) or close clinical monitoring. These patients underwent cognitive assessments at baseline and before commencement of treatment (77) then 6 months later (65). Results. Compared with baseline assessments, men administered androgen suppression monotherapy performed worse in 2/12 tests of attention and memory.
    [Show full text]
  • Goserelin (Zoladex)
    Goserelin (Zoladex) This booklet explains what goserelin is, when it may be prescribed, how it works and what side effects may occur. Goserelin is the generic (non‑branded) name of the drug and how it’s referred to in this booklet. Its current brand name is Zoladex. This information is by Breast Cancer Care. We are the only specialist UK‑wide charity that supports people affected by breast cancer. We’ve been supporting them, their family and friends and campaigning on their behalf since 1973. Today, we continue to offer reliable information and personal support, over the phone and online, from nurses and people who’ve been there. We also offer local support across the UK. From the moment you notice something isn’t right, through to treatment and beyond, we’re here to help you feel more in control. For breast cancer care, support and information, call us free on 0808 800 6000 or visit breastcancercare.org.uk Visit breastcancercare.org.uk 3 What is goserelin? Goserelin is a type of hormone therapy used to treat breast cancer in pre-menopausal women (women who have not been through the menopause). It is given as an injection into the abdomen (belly). It can also be used to try to preserve fertility during chemotherapy (see page 4). Goserelin as a treatment for breast cancer How does it work? Some breast cancers are stimulated to grow by the hormone oestrogen. Before the menopause, oestrogen is mainly produced in the ovaries. Goserelin switches off this production by interfering with hormone signals from the brain that control how the ovaries work.
    [Show full text]
  • Triptorelin, Goserelin and Leuprorelin for Prostate
    789FM.1 GONADORELIN ANALOGUES (GnRHa): TRIPTORELIN, GOSERELIN, LEUPRORELIN FOR PROSTATE CANCER - AMBER RECOMMENDATION GUIDELINE This guideline provides prescribing and monitoring guidance for triptorelin, goserelin and Leuprorelin use in prostate cancer. It should be read in conjunction with the Summary of Product Characteristics (SPC), available on www.medicines.org.uk/emc, and the BNF. BACKGROUND AND INDICATIONS FOR USE There is no conclusive evidence to suggest that any one GnRHa is more effective or has fewer side effects than another for the treatment of prostate cancer.5, 7-9 Available evidence suggests that GnRHa are similar in effectiveness to surgical castration. They have the same licensed indications in the treatment of prostate cancer (Appendix 1). Appendix 2 compares doses, administration frequency and costs.1-4, 9-13 Triptorelin 22.5 mg (six monthly injection) is the 1st choice GnRHa for treatment of metastatic prostate cancer patients on life-long treatment on the Bucks formulary. This is because it is: • Administered via a smaller sized needle (20 gauge) compared to goserelin LA 10.8 mg (14 gauge), thus minimising discomfort to patients.9 • The least expensive in terms of drug and administration costs (Appendix 2).1-4, 9-13 Triptorelin 22.5 mg (six monthly injection) is not preferred in: • Patients newly initiated GnRHa because the first dose should be a monthly preparation (Decapeptyl® SR 3 mg) in order to check that the product is tolerated prior to changing to the six monthly preparation.14 • Anticoagulated patients. This is because triptorelin is an intramuscular (IM) injection. Subcutaneously administered GnRHa (goserelin or leuprorelin) may be preferable.9 RESPONSIBILITIES Hospital specialist 1.
    [Show full text]
  • Luteal Support with Very Low Daily Dose of Human Chorionic Gonadotropin After Fresh Embryo Transfer As an Alternative to Cycle S
    pharmaceuticals Article Luteal Support with very Low Daily Dose of Human Chorionic Gonadotropin after Fresh Embryo Transfer as an Alternative to Cycle Segmentation for High Responders Patients Undergoing Gonadotropin-Releasing Hormone Agonist-Triggered IVF Andrea Roberto Carosso 1,*,† , Stefano Canosa 1,† , Gianluca Gennarelli 1 , Marta Sestero 1, Bernadette Evangelisti 1, Lorena Charrier 2 , Loredana Bergandi 3 , Chiara Benedetto 1,‡ and Alberto Revelli 1,‡ 1 Obstetrics and Gynecology 1U, Physiopathology of Reproduction and IVF Unit, Department of Surgical Sciences, Sant’Anna Hospital, University of Torino, 10042 Turin, Italy; [email protected] (S.C.); [email protected] (G.G.); [email protected] (M.S.); [email protected] (B.E.); [email protected] (C.B.); [email protected] (A.R.) 2 Department of Public Health and Pediatrics, University of Torino, Via Santena, 5 bis, 10126 Torino, Italy; [email protected] 3 Department of Oncology, University of Torino, Via Santena 5 bis, 10126 Torino, Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-333-8111155 or +39-011-3135763 † These authors contributed equally to this work. Citation: Carosso, A.R.; Canosa, S.; ‡ These authors jointly supervised this work. Gennarelli, G.; Sestero, M.; Evangelisti, B.; Charrier, L.; Bergandi, Abstract: The segmentation of the in vitro fertilization (IVF) cycle, consisting of the freezing of L.; Benedetto, C.; Revelli, A. Luteal all embryos and the postponement of embryo transfer (ET), has become popular in recent years, Support with very Low Daily Dose of Human Chorionic Gonadotropin after with the main purpose of preventing ovarian hyperstimulation syndrome (OHSS) in patients with Fresh Embryo Transfer as an high response to controlled ovarian stimulation (COS).
    [Show full text]
  • Antiprogestins, a New Form of Endocrine Therapy for Human Breast Cancer1
    [CANCER RESEARCH 49, 2851-2856, June 1, 1989] Antiprogestins, a New Form of Endocrine Therapy for Human Breast Cancer1 Jan G. M. Klijn,2Frank H. de Jong, Ger H. Bakker, Steven W. J. Lamberts, Cees J. Rodenburg, and Jana Alexieva-Figusch Department of Medical Oncology (Division of Endocrine Oncology) [J. G. M. K., G. H. B., C. J. K., J. A-F.J, Dr. Daniel den Hoed Cancer Center, and Department of Endocrinology ¡F.H. d. J., S. W. ]. L.J, Erasmus University, Rotterdam, The Netherlands ABSTRACT especially pronounced effects on the endometrium, decidua, ovaries, and hypothalamo-pituitary-adrenal axis. With regard The antitumor, endocrine, hematological, biochemical, and side effects of chronic second-line treatment with the antiprogestin mifepristone (RU to clinical practice, the drug has currently been used as a contraceptive agent or abortifacient as a result of its antipro 486) were investigated in 11 postmenopausal patients with metastatic breast cancer. We observed one objective response, 6 instances of short- gestational properties (2, 22-24). Based on its antiglucocorti term stable disease, and 4 instances of progressive disease. Mean plasma coid properties, this drug has been used or has been proposed concentrations of adrenocorticotropic hormone (/' < 0.05), cortisol (/' < for treatment of conditions related to excess corticosteroid 0.001), androstenedione (/' < 0.01), and estradici (P < 0.002) increased production such as Cushing's syndrome (19, 25-27) and for significantly during treatment accompanied by a slight decrease of sex treatment of lymphomas (24) and glaucoma (28); because of its hormone binding globulin levels, while basal and stimulated gonadotropi effects on the immune system, the drug has been suggested to levels did not change significantly.
    [Show full text]